Back to mobile site

Guggenheim Reiterates Buy Rating on Pfizer (PFE)

April 13, 2026 6:58 AM EDT Send to a Friend
Guggenheim analyst Vamil Divan reiterated a Buy rating and $36.00 price target on Pfizer (NYSE: PFE).The analyst commented: "We are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login